Pacira BioSciences Reports 6% Revenue Growth and Net Income Turnaround in Q2 2026

Pacira BioSciences, Inc. reported a total revenue of $192.4 million for the second quarter of 2026, marking a 6% increase from $181.1 million in the same period of 2025. The growth was driven primarily by net product sales, which rose to $190.5 million, up from $180.3 million year-over-year. Notably, the company achieved a net income of $4.7 million, compared to a net loss of $4.8 million in the prior year, reflecting a significant turnaround in profitability. For the first half of 2026, total revenues also increased by 6% to $369.8 million, with net income reaching $7.6 million, compared to a loss of $35,000 in the first half of 2025.

In terms of operational changes, Pacira completed the divestiture of its iovera° business to Zimmer, Inc. on July 31, 2026, for up to $140 million, including an upfront payment of $70 million. This strategic move is expected to allow Pacira to focus more on its core products, EXPAREL and ZILRETTA, while also collaborating with Zimmer on advancing the iovera° spasticity program. The company also reported an increase in cash and cash equivalents to $205.9 million as of June 30, 2026, up from $158.5 million at the end of 2025, indicating improved liquidity.

Pacira's product sales showed varied performance, with EXPAREL sales increasing by 3% to $147.8 million and ZILRETTA sales rising by 4% to $32.6 million in the second quarter. The company also noted a significant increase in sales of bupivacaine liposome injectable suspension for veterinary use, which surged over 100% in the quarter. The overall increase in product sales was partially offset by a decrease in royalty revenue, which fell to $1.9 million from $0.8 million in the previous year.

The company’s total operating expenses for the second quarter were $188.1 million, up from $172.6 million in the prior year, primarily due to increased selling, general, and administrative expenses. Research and development expenses also rose, reflecting ongoing investments in clinical trials and product development. Despite the increase in expenses, the company managed to maintain a gross margin of 77% for the quarter, consistent with the previous year.

Looking ahead, Pacira remains optimistic about its growth trajectory, particularly with the anticipated topline data from its Phase 2 clinical study of PCRX-201 expected by the end of 2026. The company plans to continue investing in its commercial resources to expand the utilization of its key products and advance its clinical-stage product candidates. Additionally, the successful divestiture of iovera° is expected to enhance its focus on core therapeutic areas, positioning Pacira for future growth in the non-opioid pain management market.